Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a
favorable prognosis when treated with either combination chemotherapy and radiation
therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have
evidence for refractory disease, is poor and new treatments are needed for patients with
progressive disease. HL has a unique tumor microenvironment consisting of a
predominance of inflammatory cells and a minority of malignant Hodgkin and Reed …